Jump to content

BioLegend: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
m +{{Authority control}} (1 ID from Wikidata); WP:GenFixes & cleanup on
No edit summary
 
Line 3: Line 3:
| name = BioLegend
| name = BioLegend
| logo =
| logo =
| type =
| type = [[Subsidiary]]
| genre =
| genre =
| foundation = 2002
| foundation = 2002
Line 21: Line 21:
| owner =
| owner =
| num_employees =
| num_employees =
| parent =
| parent = [[Revvity]]
| divisions =
| divisions =
| subsid =
| subsid =
Line 29: Line 29:
}}
}}


'''BioLegend''' is a global developer and manufacturer of [[antibody|antibodies]] and [[reagent]]s used in [[biomedical research]] located in [[San Diego, California]].<ref>{{cite web|url=http://www.laboratorytalk.com/news/cmr/cmr148.html |title=Antibodies and conjugates for biomedical research: News from Cambridge BioScience |accessdate=2009-07-21 |url-status=dead |archiveurl=https://web.archive.org/web/20110718232559/http://www.laboratorytalk.com/news/cmr/cmr148.html |archivedate=2011-07-18 }}</ref> It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the United Kingdom. BioLegend manufactures products in the areas of neuroscience, cell immunophenotyping, [[cytokine]]s and [[chemokine]]s, adhesion, cancer research, T regulatory cells, [[stem cell]]s, innate [[Immunity (medical)|immunity]], cell-cycle analysis, [[apoptosis]], and modification-specific antibodies. Reagents are created for use in [[flow cytometry]], proteogenomics, [[ELISA]], [[immunoprecipitation]], [[Western blot]]ting, [[immunofluorescence microscopy]], [[immunohistochemistry]], and [[in vitro]] or [[in vivo]] functional assays.<ref>{{cite web|url=http://www.pr-inside.com/perkinelmer-and-biolegend-announce-custom-r1246905.htm |title=PerkinElmer and BioLegend Announce Custom Immunoassay Development Collaboration for Drug Discovery Research |accessdate=2009-07-21 |url-status=dead |archiveurl=https://web.archive.org/web/20120313203444/http://www.pr-inside.com/perkinelmer-and-biolegend-announce-custom-r1246905.htm |archivedate=2012-03-13 }}</ref>
'''BioLegend''' is a global developer and manufacturer of [[antibody|antibodies]] and [[reagent]]s used in [[biomedical research]] located in [[San Diego, California]].<ref>{{cite web|url=http://www.laboratorytalk.com/news/cmr/cmr148.html |title=Antibodies and conjugates for biomedical research: News from Cambridge BioScience |accessdate=2009-07-21 |url-status=dead |archiveurl=https://web.archive.org/web/20110718232559/http://www.laboratorytalk.com/news/cmr/cmr148.html |archivedate=2011-07-18 }}</ref> It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the United Kingdom. In July 2021, BioLegend was acquired by [[PerkinElmer]] for $5.25 billion and now operates as [[Revvity]].<ref>{{cite news |title=PerkinElmer to Acquire Antibody and Reagent Leader BioLegend |url=https://www.biospace.com/article/perkinelmer-to-acquire-antibody-and-reagent-leader-biolegend/ |access-date=20 March 2024 |work=BioSpace |date=26 July 2021}}</ref> BioLegend manufactures products in the areas of neuroscience, cell immunophenotyping, [[cytokine]]s and [[chemokine]]s, adhesion, cancer research, T regulatory cells, [[stem cell]]s, innate [[Immunity (medical)|immunity]], cell-cycle analysis, [[apoptosis]], and modification-specific antibodies. Reagents are created for use in [[flow cytometry]], proteogenomics, [[ELISA]], [[immunoprecipitation]], [[Western blot]]ting, [[immunofluorescence microscopy]], [[immunohistochemistry]], and [[in vitro]] or [[in vivo]] functional assays.<ref>{{cite web|url=http://www.pr-inside.com/perkinelmer-and-biolegend-announce-custom-r1246905.htm |title=PerkinElmer and BioLegend Announce Custom Immunoassay Development Collaboration for Drug Discovery Research |accessdate=2009-07-21 |url-status=dead |archiveurl=https://web.archive.org/web/20120313203444/http://www.pr-inside.com/perkinelmer-and-biolegend-announce-custom-r1246905.htm |archivedate=2012-03-13 }}</ref>


== History ==
== History ==

Latest revision as of 15:58, 20 March 2024

BioLegend
Company typeSubsidiary
IndustryBiotechnology
Founded2002
Headquarters
San Diego, California
,
U.S.
Area served
Worldwide
Key people
Gene Lay, D.V.M., Founder and CEO
ProductsAntibodies, ELISA Kits and Sets, Recombinant Proteins, Custom Assay Development, Buffers and Solutions
ParentRevvity
Websitebiolegend.com

BioLegend is a global developer and manufacturer of antibodies and reagents used in biomedical research located in San Diego, California.[1] It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the United Kingdom. In July 2021, BioLegend was acquired by PerkinElmer for $5.25 billion and now operates as Revvity.[2] BioLegend manufactures products in the areas of neuroscience, cell immunophenotyping, cytokines and chemokines, adhesion, cancer research, T regulatory cells, stem cells, innate immunity, cell-cycle analysis, apoptosis, and modification-specific antibodies. Reagents are created for use in flow cytometry, proteogenomics, ELISA, immunoprecipitation, Western blotting, immunofluorescence microscopy, immunohistochemistry, and in vitro or in vivo functional assays.[3]

History

[edit]

BioLegend was founded by CEO, Gene Lay, D.V.M., who was also the co-founder of PharMingen. In 2011, BioLegend co-developed and introduced Brilliant Violet(TM)-conjugated antibodies, using a novel fluorophore based on Nobel Prize-winning chemistry developed by Sirigen.[4] In 2018, BioLegend introduced TotalSeq™ antibody-oligonucleotide conjugates for use in single cell proteogenomics analysis. BioLegend continued expansion and moved into a new 8 acre campus at BioLegend Way in 2019 with state of the art facilities designed to accommodate up to 1000 employees.

References

[edit]
  1. ^ "Antibodies and conjugates for biomedical research: News from Cambridge BioScience". Archived from the original on 2011-07-18. Retrieved 2009-07-21.
  2. ^ "PerkinElmer to Acquire Antibody and Reagent Leader BioLegend". BioSpace. 26 July 2021. Retrieved 20 March 2024.
  3. ^ "PerkinElmer and BioLegend Announce Custom Immunoassay Development Collaboration for Drug Discovery Research". Archived from the original on 2012-03-13. Retrieved 2009-07-21.
  4. ^ "BioLegend Company Profile". Archived from the original on 2017-04-25. Retrieved 2009-07-21.
Retrieved from "https://en.wikipedia.org/w/index.php?title=BioLegend&oldid=1214696540"